Clinical trials: Healthy Volunteers, Aged
Healthy
Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects
This study will evaluate the pharmacologic effects of exposure to darifenacin and tolterodine on cardiovascular parameters in healthy subjects 50 years of age and older
- Trial name
- NCT00413790
- Testing
- Darifenacin, Tolterodine
- Where
- 12 sites in United States
- Volunteers
- 162 people
- Sponsor
- Novartis
Healthy
Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of MYO-029
This is a multiple dose study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of an investigational new drug.
- Trial name
- NCT00563810
- Testing
- MYO-029
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Healthy Volunteers, Influenza
Study to Assess Safety and Immunogenicity of an Egg-based H5N8 Influenza Vaccine at Multiple Dose Levels Adjuvanted With Matrix-M in Healthy Participants 18 Years of Age and Above.
The study aims to evaluate an egg-based H5N8 influenza vaccine up to 3 dose levels (low, medium, and high dose) given with or without adjuvant to see if the adjuvant improves vaccine effectiveness.
- Trial name
- NCT07779408
- Testing
- Flu H5 egg pandemic low dose vaccine, with adjuvant, Flu H5 Egg Pandemic medium dose vaccine, with adjuvant, Flu H5 Egg Pandemic high dose vaccine, with adjuvant
- Where
- 16 sites in United States
- Volunteers
- 640 people, healthy volunteers welcome
- Sponsor
- Sanofi
Influenza, Healthy
A Study to Assess the Safety and Immunogenicity of M-001 Influenza Vaccine as a Primer to TIV in Elderly Volunteers
"Multimeric-001" (M-001) has been recently developed, containing conserved, common linear influenza epitopes that activate both cellular and humoral arms of the immune system against a wide variety of influenza A and B strains.
- Trial name
- NCT01419925
- Testing
- Two Multimeric-001 administrations followed by TIV, One administration of Multimeric-001 followed by TIV, One administration of adjuvanted M-001 followed by TIV
- Where
- Israel
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- BiondVax Pharmaceuticals ltd.
Healthy
Cardiovascular Effects of Incremental Diesel Exhaust Inhalation in Middle-Aged Healthy GSTM1 Null Human Volunteers
Purpose: A growing body of epidemiological data suggests an increased risk of cardiovascular events associated with air pollutants.
- Trial name
- NCT01548625
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Environmental Protection Agency (EPA)
Virus, Zika, Zika Virus Disease
Safety, Immunogenicity, and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy Participants
The purpose of this study is to describe the safety, tolerability and immunogenicity of two doses of purified inactivated Zika virus vaccine (PIZV) given 28 days apart.
- Conditions
- Virus, Zika, Zika Virus Disease, Flavivirus Infections, Healthy Participants
- Trial name
- NCT03343626
- Testing
- PIZV
- Where
- 9 sites in United States, Puerto Rico
- Volunteers
- 271 people, healthy volunteers welcome
- Sponsor
- Takeda
Healthy Subjects, Immune Cells (Mucosal and Systemic)
CIRCAdian Rhythm of the IMMune Age IndeX (IMMAX)
The goal of this observational study is to evaluate the influence of circadian rhythms on the determination of an individual's immune age. The biomarker IMMAX was calculated for 50 participants aged 20-69 at 8 a.m., 1 p.m.
- Trial name
- CIRCA-IMMAX (NCT07169721)
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Leibniz Research Centre for Working Environment and Human Factors
Lyme Disease
A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine
The purpose of this study is to learn about the safety effects of the Lyme disease vaccine (called VLA15), and its ability to protect people from Lyme disease after a 5th dose of the vaccine.
- Trial name
- NCT07500506
- Testing
- VLA15
- Where
- 22 sites in United States, Canada
- Volunteers
- 1,712 people, healthy volunteers welcome
- Sponsor
- Pfizer
Aging, Frailty
Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults
This is a randomized, double-blind, placebo-controlled, two-arm crossover clinical trial evaluating the effects of nicotinamide mononucleotide (NMN) combined with trimethylglycine (TMG) supplementation, compared to NMN alone.
- Conditions
- Aging, Frailty, Exercise Tolerance, Healthy Male and Female Subjects
- Trial name
- NCT07144527
- Testing
- NMN and TMG (Euexia), Nicotinamide Mononucleotide (NMN)
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Scott Silveira
Healthy Volunteers
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of BC 007 in Healthy Subjects
Berlin Cures develops BC 007 to treat patients suffering from diseases (chronic heart failure, pulmonary hypertension, chronic fatigue syndrome etc.) which are associated with functional autoantibodies (AAB) directed against…
- Trial name
- NCT02955420
- Testing
- BC 007, NaCl 0.9 %
- Where
- Germany
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Berlin Cures GmbH
Healthy Volunteer
Suvarnaprashana Pilot Study in Healthy Nepali Children Aged 2-5 Years
Introduction This prospective, single-site, non-randomized, open-label controlled pilot study aims to generate preliminary evidence on the short-term safety and potential immunomodulatory effects of Suvarnaprashana (SP), a…
- Trial name
- SPPILOTNP (NCT07724561)
- Testing
- Suvarnaprashana (Ayurvedic gold-based formulation)
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Ayurveda Research and Training Center
Influenza
Safety and Immune Response of Increasing Doses of OVX836 After Intramuscular or Intranasal Administrations in Healthy Subjects
The present study is a first-in-man clinical trial evaluating OVX836, a recombinant broad spectrum vaccine for Influenza. This clinical trial will evaluate the safety and the immune response of increasing doses of OVX836 after…
- Trial name
- NCT03594890
- Testing
- OVX836 (Intramuscular), OVX836 (Intranasal)
- Where
- Belgium
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Osivax
Healthy
Frequency Response of the Foot-Yangming Stomach Channel: Zu-San-Li and Xian-Gu
The main purpose of this study is to detect the frequency response in the electric wave transmission through the channels inside human body.
- Trial name
- YCFR (NCT01362166)
- Where
- Taiwan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- China Medical University Hospital
Healthy
A Crossover Study to Evaluate the Relative Oral Bioavailability and Food Effect After Single Dose Administration of JNJ-54861911 Tablet in Healthy Elderly Participants
The purpose of this study is to assess the effect of a high-fat/high-caloric breakfast on the rate and extent of absorption of the single oral dose of 25 mg JNJ-54861911 test formulation in healthy elderly participants.
- Trial name
- NCT02355561
- Testing
- JNJ-54861911 (Treatment A), JNJ-54861911 (Treatment B), JNJ-54861911 (Treatment C)
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy Participants
Phase 1 Single and Multiple Ascending Dose of LTG-321 in Healthy Participants
This is a first-in-human, randomized, double-blind, placebo-controlled Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics…
- Trial name
- NCT07110610
- Testing
- LTG-321
- Where
- New Zealand
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Latigo Biotherapeutics
Healthy
Study Evaluating The Safety And Tolerability Of Administration Of Single Oral Doses Of SAM-760 To Healthy Subjects
This study will assess the safety and tolerability of ascending single oral doses of SAM-760 in healthy young adult and healthy elderly subjects.
- Trial name
- NCT00948662
- Testing
- SAM-760, ketoconazole
- Where
- France
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Pfizer
Encephalitis, Tick-borne
Safety Study in Volunteers From 16 to 65 Years of Age: FSME IMMUN NEW vs. ENCEPUR
The purpose of this study is to assess the safety of a vaccination schedule consisting of two vaccinations (21-35 days apart) with the tick-borne encephalitis (TBE) vaccine FSME-IMMUN NEW (5 consecutive lots) in comparison to…
- Trial name
- NCT00161824
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- 7 sites in Poland
- Volunteers
- 3,800 people, healthy volunteers welcome
- Sponsor
- Pfizer
Adult, Healthy Participants
A Study to Learn About the Safety and Immune Responses of RSVpreF in Older Adults
The purpose of this study is to learn about the safety, tolerability, and immune response of the RSVpreF vaccine in healthy older adults. Participants will take part in this study for about 6 months.
- Trial name
- NCT07819097
- Testing
- RSVpreF
- Where
- 15 sites in United States, China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Pfizer
Ebola
Study to Evaluate the Immunogenicity and Safety of an Ebola Virus (EBOV) Glycoprotein (GP) Vaccine in Healthy Subjects
This is a randomized, observer-blind, placebo-controlled trial in male and female subjects ≥18 to <50 years of age. Subjects will be healthy adults based on history, physical examination, and baseline clinical laboratory testing.
- Trial name
- NCT02370589
- Testing
- Base Dose EBOV GP Vaccine, 2x Base Dose EBOV GP Vaccine, 4x Base Dose EBOV GP Vaccine
- Where
- 3 sites in Australia
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Novavax
Solid Tumours
To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers
Study to assess the effect of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc interval in healthy male volunteers.
- Trial name
- NCT02056392
- Testing
- Selumetinib, Moxifloxacin
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- AstraZeneca